Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
REDWOOD CITY, Calif.–(BUSINESS WIRE)–
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York.
Details of the event are as follows:
Date: Thursday, June 4, 2026
Time: 7:35a.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260514519453/en/
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
[email protected]
Penelope Belnap
Precision AQ
[email protected]
KEYWORDS: California New York United States North America
INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology
MEDIA: